Microscopic polyangiitis (MPA) is a rare autoimmune disease that causes inflammation (vasculitis) in the body’s small blood vessels, including capillaries, venules, and arterioles.
It belongs to the ANCA-associated vasculitis family.
Immune System Attack: MPA is an ANCA-associated vasculitis (AAV).
Most people, around 70%, test positive for antineutrophil cytoplasmic antibodies (ANCA), specifically targeting myeloperoxidase (MPO-ANCA).
Pauci-Immune Nature:
Unlike some other vasculitis conditions, MPA features necrotizing inflammation with little to no immune-complex deposit (“pauci-immune”) and no granulomas, which helps distinguish it from granulomatosis with polyangiitis.
General: Fever, fatigue, weight loss, joint and muscle pain.
Commonly Affected Organs: Kidneys (approx. 80%): Causes necrotizing and crescentic glomerulonephritis, leading to blood and protein in the urine or rapidly declining kidney function.
Lungs (20%–50%): Can cause pulmonary capillaritis, alveolar hemorrhage (hemoptysis), shortness of breath or interstitial lung fibrosis.
Skin: Frequently causes palpable purpura or other skin lesions such as ulcers, or nodules
Nerves and Joints: Can lead to mononeuritis multiplex (nerve damage causing numbness/tingling/weakness) as well as joint and muscle aches.
Diagnosis and Treatment
Diagnosis: Confirmed through a combination of blood tests (ANCA, inflammatory markers like ESR/CRP), urine analysis, and a tissue biopsy from the kidney, skin, or lung. Blood tests: usually MPO-ANCA (p-ANCA) positive. Urinalysis and kidney function Biopsy (usually kidney) showing “pauci-immune” vasculitis Chest imaging if lungs are involved
Treatment: Managed in two phases—induction therapy followed by maintenance therapy.
Induction: High-dose corticosteroids combined with immunosuppressants like rituximab or cyclophosphamide, and plasma exchange in severe, life-threatening cases.
Maintenance: Lower-dose or maintenance drugs (such as azathioprine, rituximab, or methotrexate) to prevent relapses.
There is no permanent cure, but aggressive early treatment helps many patients enter long-term remission, though regular monitoring is necessary because relapses can happen.
Treatment Induction: High-dose glucocorticoids plus rituximab or cyclophosphamide
Severe cases: Plasma exchange may be considered, and avacopan is an option that can reduce steroid exposure.
Maintenance:Typically rituximab or azathioprine, often for 18+ months, with a steroid taper
Early treatment greatly improves survival and kidney outcomes, but relapses are common, so long-term monitoring is needed.
